ESC Premium Access

Empagliflozin reduces mortality and hospitalisation for heart failure irrespective of cardiovascular risk score at baseline

Congress Presentation

About the speaker

Doctor David Fitchett

St. Michael's Hospital, Toronto (Canada)
18 presentations
0 follower

5 more presentations in this session

Sex-specific analysis on efficacy and safety of statins: a systematic review and quantitative meta-analysis

Speaker: Miss M. Schreuder (Rotterdam, NL)


Changes in plasma lipid species following pravastatin treatment predict cardiovascular outcomes and represent a measure of the relative risk reduction in secondary prevention

Speaker: Professor P. Meikle (Melbourne, AU)


Empagliflozin reduces mortality in patients with type 2 diabetes and a history of left ventricular hypertrophy: a sub-analysis of the EMPA-REG OUTCOME trial

Speaker: Professor S. Verma (Toronto, CA)


LDL-C treatment patterns and associated outcomes in patients with type 2 diabetes and CVD: insights from TECOS

Speaker: Professor G. De Ferrari (Turin, IT)


Reduction in systolic blood pressure with semaglutide treatment is not due to weight loss alone: data from SUSTAIN 1-5

Speaker: Professor S. Bain (Swansea, GB)


Access the full session

Poster Session 2 - Cardiovascular risk and its modification

Speakers: Doctor D. Fitchett, Miss M. Schreuder, Professor P. Meikle, Professor S. Verma, Professor G. De Ferrari...

About the event


ESC Congress 2018

7 November - 29 August 2018

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb